FDA Approves METHADONE HYDROCHLORIDE — SpecGx LLC

SpecGx LLC received FDA approval on April 27, 2004, for its Abbreviated New Drug Application (ANDA040517) for OROXTM METHADONE HYDROCHLORIDE, potentially introducing a generic alternative that may impact market pricing dynamics for this critical opioid agonist. The approval of the oral formulation underscores SpecGx's footprint in the controlled substance supply chain, addressing demand amidst ongoing debates over opioid accessibility and cost management.